REDUX/PONDIMIN WITHDRAWALS PROVOKE QUESTIONS OF OFF-LABEL USE PROVISIONS IN FDA REFORM BILL; FEN-PHEN CITED IN KENNEDY ATTEMPT TO CHANGE DEVICE PROVISIONS
The Sept. 15 withdrawal from the market of Wyeth-Ayerst/Interneuron's anti-obesity drug Redux (dexfenfluramine) and Wyeth's Pondimin (fenfluramine) has raised concerns for some House members over provisions in the FDA reform bill (HR 1411) that would allow companies to promote off-label uses of products, Rep. Brown (D-Ohio) said at a Sept. 17 Commerce Health Subcommittee mark-up of the bill.
You may also be interested in...
Strong efficacy and a clean safety profile – with no cardiovascular signal – in another Phase III study bode well for filings of Zogenix's ZX008 in the fourth quarter.
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials